Want to see AMS full AI Analyst Report?
AMS Stock Chart & Stats
$1.46
$0.01(0.68%)
At close: 4:00 PM EDT
$1.46
$0.01(0.68%)
Day’s Range― - ―
52-Week Range$1.25 - $3.11
Previous CloseN/A
Volume3.28K
Average Volume (3M)78.93K
Market Cap
$10.04M
Enterprise Value$27.32
Total Cash (Recent Filing)$6.51M
Total Debt (Recent Filing)$20.52M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Nov 18, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding6,650,000
10 Day Avg. Volume41,017
30 Day Avg. Volume78,931
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.58
Price to Sales (P/S)0.50
P/FCF Ratio-3.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$29.95M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthDouble-digit quarterly and first-half growth indicates improving demand and utilization across the treatment network. Sustained expansion in provider-site activity can support recurring contractual revenue if the company continues adding capacity and retaining hospital relationships.
Direct Services And Proton GrowthStrong growth in direct patient services and proton therapy demonstrates increasing treatment volumes and reimbursement support in higher-value offerings. A broader mix of active treatment sites could improve the company's structural revenue base and reduce reliance on any single service.
Improved Cash GenerationPositive operating cash flow and materially higher liquidity improve the company's ability to fund operations and execute site upgrades. The improvement provides greater resilience than prior periods, although continued consistency is needed before cash generation can be considered fully established.
Bears Say
Persistent UnprofitabilityRevenue growth has not yet translated into durable profitability, with low gross margin and negative operating and net income. Continued losses limit internally funded expansion, weaken equity returns, and leave execution dependent on cost control and improved site economics.
Refinancing And Default RiskThe amended credit arrangement provides time but does not remove structural financing pressure. Covenant defaults, restrictions, required asset-sale efforts, and a large 2027 obligation could constrain investment and force unfavorable refinancing or disposition decisions.
Leasing And Collections HeadwindsThe lost leasing agreement reduces part of the domestic revenue base, while the receivables allowance highlights collection and billing risk. These issues may pressure recurring cash receipts and show that growth in other services has not eliminated customer and execution dependencies.
American Shared Hospital Services News
AMS FAQ
What was American Shared Hospital Services’s price range in the past 12 months?
American Shared Hospital Services lowest stock price was $1.25 and its highest was $3.11 in the past 12 months.
What is American Shared Hospital Services’s market cap?
American Shared Hospital Services’s market cap is $10.04M.
When is American Shared Hospital Services’s upcoming earnings report date?
American Shared Hospital Services’s upcoming earnings report date is Nov 18, 2026 which is in 86 days.
How were American Shared Hospital Services’s earnings last quarter?
American Shared Hospital Services released its earnings results on Aug 13, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.05.
Is American Shared Hospital Services overvalued?
According to Wall Street analysts American Shared Hospital Services’s price is currently Overvalued.
Does American Shared Hospital Services pay dividends?
American Shared Hospital Services does not currently pay dividends.
What is American Shared Hospital Services’s EPS estimate?
American Shared Hospital Services’s EPS estimate is 0.01.
How many shares outstanding does American Shared Hospital Services have?
American Shared Hospital Services has 6,650,000 shares outstanding.
What happened to American Shared Hospital Services’s price movement after its last earnings report?
American Shared Hospital Services reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went up 3.896%.
Which hedge fund is a major shareholder of American Shared Hospital Services?
Currently, no hedge funds are holding shares in AMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
American Shared Hospital Services
American Shared Hospital Services specializes in leasing advanced radiosurgery and radiation therapy equipment to healthcare providers. The company offers Gamma Knife stereotactic radiosurgery systems, a non-invasive technology used to treat conditions such as malignant and benign brain tumors, arteriovenous malformations, and trigeminal neuralgia. They also facilitate financing for Leksell Gamma Knife units. Additionally, the firm operates proton beam radiation therapy centers in Orlando, Florida, and Long Beach, California. Customers further benefit from comprehensive support encompassing planning, installation, reimbursement guidance, and marketing strategies. As of December 31, 2021, their portfolio included 115 active Gamma Knife units across the United States, complemented by two units in South America (Lima, Peru, and Guayaquil, Ecuador), and one proton beam radiation therapy system. Established in 1980, American Shared Hospital Services maintains its headquarters in San Francisco, California.
AMS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated clear operational progress: double‑digit revenue growth, strong expansion of direct patient services (≈+40% Q2), meaningful proton therapy growth (~+22%), international throughput gains after technology upgrades, and robust cash generation (operating cash flow $4.4M YTD; cash up >80% vs year‑end). These positives are tempered by near‑term balance sheet and earnings noise: a $909K receivable allowance, $285K legal costs, a YoY Q2 adjusted EBITDA decline (from $1.7M to $1.3M), and an amended loan with potential sale provisions and refinancing risk ( ~$15.5M due by June 2027). Overall, operational momentum and improved liquidity/supporting financing actions outweigh the balance‑sheet and one‑time challenges, though capital structure risk remains the primary area of concern.View all AMS earnings summariesTechnical Analysis
Community Health
―
Concord Medical Services
―
Surgery Partners
―
PACS Group Inc
―
Ardent Health Partners, Inc.
―
Ownership Overview
34.29% Insiders
6.56% Mutual Funds
0.88% Other Institutional Investors
57.03% Public Companies and
Individual Investors